Abstract
1 Serum HDL cholesterol measured at the end of a 5 year multifactorial primary prevention trial, aimed to reduce risk factor levels and incidence of ischaemic heart disease, revealed quite low values in drug-treated subjects. 2 Analysis of subgroups treated with beta-adrenoceptor blocking agents (mainly pindolol) alone or in different combinations with diuretics showed inconsistent effects of beta-adrenoceptors blockers on serum HDL cholesterol. HDL cholesterol levels in patients treated with pindolol with or without a diuretic were not different from those of the risk-free control group. 3 Subjects on combined beta-adrenoceptor blocker-hypolipidaemic treatments had lower HDL-cholesterol than those on hypolipidaemic agents alone. 4 Withdrawal of pindolol at the end of the trial caused a small but significant increase in serum HDL cholesterol in a small subgroup of mildly hypertensive patients. Thus, pindolol appears to have slightly reduced serum HDL cholesterol but the relevance of this small decrease on the incidence of ischaemic heart disease is questionable.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Helgeland A., Hjermann I., Leren P., Enger S., Holme I. High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J. 1978 Aug 5;2(6134):403–403. doi: 10.1136/bmj.2.6134.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kannel W. B., Castelli W. P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979 Jan;90(1):85–91. doi: 10.7326/0003-4819-90-1-85. [DOI] [PubMed] [Google Scholar]
- Kristensen B. O. Effect of long-term treatment with beta-blocking drugs on plasma lipids and lipoproteins. Br Med J (Clin Res Ed) 1981 Jul 18;283(6285):191–192. doi: 10.1136/bmj.283.6285.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lehtonen A., Viikari J. Long-term effect of sotalol on plasma lipids. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):405s–407s. doi: 10.1042/cs057405s. [DOI] [PubMed] [Google Scholar]
- Leren P., Foss P. O., Helgeland A., Hjermann I., Holme I., Lund-Larsen P. G. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet. 1980 Jul 5;2(8184):4–6. doi: 10.1016/s0140-6736(80)92888-3. [DOI] [PubMed] [Google Scholar]
- Miettinen T. A., Huttunen J. K., Strandberg T., Naukkarinen V., Mattila S., Kumlin T. Lowered HDL cholesterol and incidence of ischaemic heart disease. Lancet. 1981 Aug 29;2(8244):478–478. doi: 10.1016/s0140-6736(81)90817-5. [DOI] [PubMed] [Google Scholar]
- Miller N. E., Thelle D. S., Forde O. H., Mjos O. D. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977 May 7;1(8019):965–968. doi: 10.1016/s0140-6736(77)92274-7. [DOI] [PubMed] [Google Scholar]
- Röschlau P., Bernt E., Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins im Serum. Z Klin Chem Klin Biochem. 1974 Sep;12(9):403–407. [PubMed] [Google Scholar]
- Streja D., Mymin D. Effect of propranolol on HDL cholesterol concentrations. Br Med J. 1978 Nov 25;2(6150):1495–1495. doi: 10.1136/bmj.2.6150.1495-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tanaka N., Sakaguchi S., Oshige K., Niimura T., Kanehisa T. Effect of chronic administration of propranolol on lipoprotein composition. Metabolism. 1976 Oct;25(10):1071–1075. doi: 10.1016/0026-0495(76)90014-7. [DOI] [PubMed] [Google Scholar]
- Waal-Manning H. J. Metabolic effects of beta-adrenoreceptor blockers. Drugs. 1976;11(Suppl 1):121–126. doi: 10.2165/00003495-197600111-00027. [DOI] [PubMed] [Google Scholar]